NeoGraph Analytics
BiotechnologyNorth America2023 – 2032

Global CRISPR Technology Market Size, Share and Trends Analysis

The Global CRISPR Technology market was valued at $2.74B in 2023 and is forecast to reach $9.27B by 2032, growing at a 14.5% CAGR.

Revenue, 2023

$2.7B

Forecast, 2032

$9.3B

CAGR, 2024-2032

14.5%

Report Coverage

North America

Code: crispr-technology-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

The global CRISPR technology market was valued at approximately $2.74 billion in 2023 and is projected to reach $9.27 billion by 2032, growing at a CAGR of 14.5%. North America leads with 42% market share, driven by robust R&D funding and regulatory approvals including Casgevy. Key applications span therapeutics, diagnostics, and agriculture, with gene editing therapeutics commanding 40% of the market. Intense competition among CRISPR Therapeutics, Intellia Therapeutics, and Editas Medicine shapes the innovation landscape.

02

Key Highlights

1

Casgevy approval marks a historic milestone, validating CRISPR-based therapeutics and accelerating pipeline development globally.

2

North America commands 42% share, driven by leading companies, funding access, and favorable regulatory frameworks.

3

Gene editing therapeutics dominate at 40% share, with oncology and rare diseases as primary growth targets.

03

Market Overview

Market Context

CRISPR technology enables precise genome editing across therapeutics, diagnostics, and agriculture. Growing prevalence of genetic disorders, expanding biotech pipelines, and breakthrough approvals like Casgevy accelerate adoption. North America dominates due to strong funding and infrastructure, while Asia Pacific emerges as the fastest-growing region.

The CRISPR technology market is experiencing high growth, valued at $2.74B in 2023 with a projected $9.27B by 2032 at 14.5% CAGR. Gene editing therapeutics lead adoption while diagnostics and agricultural applications expand rapidly.

Market Stage

High growth

Adoption Level

Growing

Key Trends

In vivo delivery via lipid nanoparticles advancing clinical pipelinesCRISPR-based diagnostics gaining traction post-pandemicAgricultural gene editing accelerating crop improvement programsIncreasing strategic collaborations between pharma and biotech firms
04

Market Forecast & Data

Market Growth Forecast
2024-2032 · CAGR 14.5%

Base Year (2023)

$2.7B

Forecast (2032)

$9.3B

CAGR (2024-2032)

14.5%

Market size by year, 2024-2032, in USD Billion.
YearMarket size ($ Billion)
2023Base year$2.74B
2024$3.14B
2025$3.59B
2026$4.11B
2027$4.71B
2028$5.39B
2029$6.17B
2030$7.07B
2031$8.09B
2032$9.27B
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Forecast Analysis

The 14.5% CAGR reflects accelerating clinical trials, expanding therapeutic applications, and increasing investment in gene editing infrastructure. Gene editing therapeutics will remain the dominant segment, while CRISPR reagents and diagnostics show strong growth potential. Regulatory clarity and delivery technology advances are critical enablers through 2032.

Regional Market Analysis
Market share and growth rate by region
Regional market analysis — market share, growth rate and largest market by region.
RegionMarket shareGrowth rateLargest market
North America42.0%13.8%United States
Europe28.0%12.4%Germany
Asia Pacific30.0%17.2%China

North America

#1
Share: 42.0%CAGR: 13.8%

Largest market: United States

Europe

#2
Share: 28.0%CAGR: 12.4%

Largest market: Germany

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
05

Market Dynamics

  • Rising prevalence of genetic disorders and demand for precision medicine
  • Casgevy approval accelerating clinical pipeline and investor confidence
  • Expanding applications in diagnostics and agricultural biotechnology
06

Market Segmentation

By Technology
Market share distribution across 4 segments
By Technology — market share by segment, in percent.
SegmentShare
CRISPR-Cas9Most widely adopted CRISPR system with the broadest clinical and research application base.55.0%
CRISPR-Cas12Gaining traction in diagnostics and multiplexed gene editing applications.20.0%
CRISPR-Cas13RNA-targeting system used primarily in diagnostics and transcriptome editing.15.0%
Other CRISPR SystemsEmerging variants including CasX, Cas14, and engineered Cas proteins for specialized applications.10.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
By Application
Market share distribution across 4 segments
By Application — market share by segment, in percent.
SegmentShare
Gene Editing TherapeuticsLargest segment driven by clinical pipeline for sickle cell disease, beta-thalassemia, and oncology applications.40.0%
CRISPR Reagents & KitsEssential tools for research laboratories enabling gene knockout, knock-in, and functional genomics studies.25.0%
DiagnosticsRapidly growing segment leveraging CRISPR-based detection platforms like SHERLOCK and DETECTR.20.0%
Agricultural BiotechnologyCrop improvement applications for disease resistance, yield enhancement, and drought tolerance.15.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.

By End User

  • Pharmaceutical & Biotech Companies
  • Academic & Research Institutes
  • Hospitals & Clinics
  • Agricultural Companies
07

Regional Analysis

1

North America

Lead: United States
CAGR: 13.8%Share: 42.0%

Dominant region driven by leading companies, strong R&D funding, and favorable regulatory approvals including Casgevy.

2

Europe

Lead: Germany
CAGR: 12.4%Share: 28.0%

Significant market supported by robust academic research, EU funding programs, and growing clinical trial activity.

3

Asia Pacific

Lead: China
CAGR: 17.2%Share: 30.0%

Fastest-growing region driven by expanding biotech infrastructure, government investment, and agricultural applications.

Country-Level Analysis

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Market share and growth rate by country
CountryShareGrowth
United States
35.0%
+13.5%
Germany
10.0%
+11.8%
China
14.0%
+19.2%
08

Competitive Landscape

C

CRISPR Therapeutics AG

Switzerland

Leader~$1.5B (2024 est.)

Pioneered the first approved CRISPR therapy Casgevy and maintains the most advanced clinical pipeline across hematology and oncology with a dominant IP portfolio.

Swiss-based leader in CRISPR gene editing with the first approved therapy Casgevy and a broad clinical pipeline spanning hematology, oncology, and autoimmune diseases.

I

Intellia Therapeutics

United States

Challenger~$800M (2024 est.)

Leading in vivo CRISPR therapeutics with nexiguran ziclumeran in Phase 3 for ATTR amyloidosis, leveraging proprietary LNP delivery technology.

US-based clinical-stage biotech pioneering in vivo CRISPR therapeutics with a proprietary LNP delivery platform targeting genetic diseases including ATTR amyloidosis.

E

Editas Medicine

United States

Follower~$600M (2024 est.)

Focused on in vivo and ex vivo gene editing with EDIT-101 for ocular diseases, advancing a diversified pipeline across multiple therapeutic areas.

US-based gene editing company advancing both in vivo and ex vivo CRISPR therapies with a focus on ocular diseases, oncology, and blood disorders.

09

Recent Developments

25
2025CRISPR Therapeutics

Expanded Casgevy commercial launch across EU and initiated Phase 2 trials for CTX112 in autoimmune indications

24
2024Intellia Therapeutics

Reported positive Phase 3 interim data for nexiguran ziclumeran in hereditary ATTR amyloidosis with NTLA-20001

24
2024Editas Medicine

Advanced EDIT-101 Phase 1/2 clinical trial for Leber Congenital Amaurosis with promising early efficacy data

10

Regulatory Landscape

FDA approved Casgevy (exagamglogene autotemcel) in December 2023, establishing regulatory precedent for CRISPR-based therapiesEMA and MHRA granted conditional marketing authorization for Casgevy, enabling European and UK market accessEvolving FDA guidance on human gene editing trials emphasizing long-term safety monitoring and off-target analysisChina's NMPA developing specific regulatory frameworks for gene editing therapeutics and agricultural applications
11

Research Methodology

Primary research

  • Expert interviews
  • Surveys
  • Industry analyst consultations

Secondary research

  • Industry reports
  • Company financials
  • Regulatory filings
  • Clinical trial databases

Validation: Triangulation method combining primary insights with cross-validated secondary sources

12

Strategic Takeaways

Investors

The $2.74B to $9.27B growth trajectory offers significant returns across therapeutics, reagents, and diagnostics segments through 2032.

Operators

Strategic partnerships and delivery technology innovation are essential to capture market share in this competitive landscape.

Policymakers

Regulatory harmonization across regions will be critical to ensuring safe, equitable CRISPR technology adoption globally.

13

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.